Skip to main content
Premium Trial:

Request an Annual Quote

GeneMachines Appoints VPs of Manufacturing, Development

NEW YORK, May 18 – GeneMachines has added two executives to its management team, the company said Friday. Terry Allread will join the company as vice president of manufacturing, and Patricia Gray will take a position as vice president of development.

The new appointments reflect a growth in the company’s sales and number of products, according to a statement.

Allread, formerly vice president of operations at ThermoFinnigan, will direct the expansion of GeneMachines’ manufacturing operations. Prior to ThermoFinnigan, Allread served as vice president, manufacturing at Spectra Physics.

As vice president of development, Patricia Gray will lead the company’s product development team. Gray has a degree in engineering from Rensselaer Polytechnic Institute and an MBA and masters in engineering in biomedical engineering from Worcester Polytechnic Institute.

GeneMachines manufactures and sells automated laboratory equipment used in the preparation and analysis of DNA samples. The San Carlos, Calif.-based company also sells equipment for synthesizing oligonucleotides and preparing DNA microarrays.  
The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.